-
1
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
[PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
Burroughs, M.11
Brass, C.A.12
Albrecht, J.K.13
Esteban, R.14
-
2
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
[PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Ferenci, P.9
Flisiak, R.10
George, J.11
Rizzetto, M.12
Shouval, D.13
Sola, R.14
Terg, R.A.15
Yoshida, E.M.16
Adda, N.17
Bengtsson, L.18
Sankoh, A.J.19
Kieffer, T.L.20
George, S.21
Kauffman, R.S.22
Zeuzem, S.23
more..
-
3
-
-
77956268467
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial
-
[PMID: 20692693 DOI: 10.1016/ S0140-673610)60934-8]
-
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716 [PMID: 20692693 DOI: 10.1016/ S0140-673610)60934-8]
-
(2010)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
Schiff, E.R.4
Vierling, J.M.5
Pound, D.6
Davis, M.N.7
Galati, J.S.8
Gordon, S.C.9
Ravendhran, N.10
Rossaro, L.11
Anderson, F.H.12
Jacobson, I.M.13
Rubin, R.14
Koury, K.15
Pedicone, L.D.16
Brass, C.A.17
Chaudhri, E.18
Albrecht, J.K.19
-
4
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
[PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
-
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
Younossi, Z.8
Foster, G.R.9
Horban, A.10
Ferenci, P.11
Nevens, F.12
Müllhaupt, B.13
Pockros, P.14
Terg, R.15
Shouval, D.16
van Hoek, B.17
Weiland, O.18
Van Heeswijk, R.19
De Meyer, S.20
Luo, D.21
Boogaerts, G.22
Polo, R.23
Picchio, G.24
Beumont, M.25
more..
-
5
-
-
0036829649
-
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002
-
National Institutes of Health, [PMID: 12407572 DOI: 10.1053/jhep.2002.37117]
-
National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36: S3-S20 [PMID: 12407572 DOI: 10.1053/jhep.2002.37117]
-
(2002)
Hepatology
, vol.36
-
-
-
6
-
-
17144404226
-
Treatment of hepatitis C: Critical appraisal of the evidence
-
[PMID: 15794731 DOI: 10.1517/14656566.6.3.399]
-
Cammà C, Licata A, Cabibbo G, Latteri F, Craxì A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005; 6: 399-408 [PMID: 15794731 DOI: 10.1517/14656566.6.3.399]
-
(2005)
Expert Opin Pharmacother
, vol.6
, pp. 399-408
-
-
Cammà, C.1
Licata, A.2
Cabibbo, G.3
Latteri, F.4
Craxì, A.5
-
7
-
-
30044437827
-
American Gastroenterological Association medical position statement on the management of hepatitis C
-
[PMID: 16401485 DOI: 10.1053/j.gastro.2005.11.011]
-
Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-230 [PMID: 16401485 DOI: 10.1053/j.gastro.2005.11.011]
-
(2006)
Gastroenterology
, vol.130
, pp. 225-230
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
8
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
[PMID: 15057920 DOI: 10.1002/hep.20119.]
-
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171 [PMID: 15057920 DOI: 10.1002/hep.20119.]
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
9
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
[PMID: 12324553 DOI: 10.1056/NEJMoa020047]
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Gonçales, F.L.6
Häussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Lin, A.12
Hoffman, J.13
Yu, J.14
-
10
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
[PMID: 14996676]
-
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676]
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
Ramadori, G.7
Bodenheimer, H.8
Bernstein, D.9
Rizzetto, M.10
Zeuzem, S.11
Pockros, P.J.12
Lin, A.13
Ackrill, A.M.14
-
11
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
[PMID: 11583749]
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749]
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.9
Albrecht, J.K.10
-
12
-
-
74049136040
-
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
-
[PMID: 19674282 DOI: 10.1111/j.1365-2893.2009.01157]
-
Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010; 17: 139-147 [PMID: 19674282 DOI: 10.1111/j.1365-2893.2009.01157]
-
(2010)
J Viral Hepat
, vol.17
, pp. 139-147
-
-
Rodriguez-Torres, M.1
Sulkowski, M.S.2
Chung, R.T.3
Hamzeh, F.M.4
Jensen, D.M.5
-
13
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
[PMID: 12939591 DOI: 10.1053/jhep.2003.50364]
-
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652 [PMID: 12939591 DOI: 10.1053/jhep.2003.50364]
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
Manns, M.P.4
Harvey, J.5
Albrecht, J.6
-
14
-
-
79955062037
-
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: An open-label study in central and Eastern Europe
-
[PMID: 21502923 DOI: 10.1097/MEG.0b013e3283458407]
-
Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. Eur J Gastroenterol Hepatol 2011; 23: 375-381 [PMID: 21502923 DOI: 10.1097/MEG.0b013e3283458407]
-
(2011)
Eur J Gastroenterol Hepatol
, vol.23
, pp. 375-381
-
-
Husa, P.1
Oltman, M.2
Ivanovski, L.3
Rehák, V.4
Messinger, D.5
Tietz, A.6
Urbanek, P.7
-
15
-
-
0036784356
-
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
-
[PMID: 12217604]
-
Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Häussinger D, Smith CI, Lin A, Pappas SC. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-506 [PMID: 12217604]
-
(2002)
J Hepatol
, vol.37
, pp. 500-506
-
-
Lee, S.S.1
Heathcote, E.J.2
Reddy, K.R.3
Zeuzem, S.4
Fried, M.W.5
Wright, T.L.6
Pockros, P.J.7
Häussinger, D.8
Smith, C.I.9
Lin, A.10
Pappas, S.C.11
-
16
-
-
79960453276
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
-
European Association for the Study of the Liver, [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
-
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
17
-
-
34047137162
-
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate
-
[PMID: 17402993 DOI: 10.1111/j.1365-2036.2007.03270]
-
Diago M, Olveira A, Solá R, Romero-Gómez M, Moreno-Otero R, Pérez R, Salmerón J, Enríquez J, Planas R, Gavilán JC, Del Olmo J, Uribarrena R, Sillero C, Benítez A, Sánchez-Galdón S, Dalmau B, Eraña L, Montoro M, Portu J, Garijo JM, Barniol R, Domínguez A, Rota R, Olcoz JL, Antón M, Pamplona X, Casanovas T, Jiménez E, Huarte M, Díaz F, Sánchez-Ruano J, Orive M, Muñoz-Sánchez M, Roset M. Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. Aliment Pharmacol Ther 2007; 25: 899-906 [PMID: 17402993 DOI: 10.1111/j.1365-2036.2007.03270]
-
(2007)
Aliment Pharmacol Ther
, vol.25
, pp. 899-906
-
-
Diago, M.1
Olveira, A.2
Solá, R.3
Romero-Gómez, M.4
Moreno-Otero, R.5
Pérez, R.6
Salmerón, J.7
Enríquez, J.8
Planas, R.9
Gavilán, J.C.10
Del Olmo, J.11
Uribarrena, R.12
Sillero, C.13
Benítez, A.14
Sánchez-Galdón, S.15
Dalmau, B.16
Eraña, L.17
Montoro, M.18
Portu, J.19
Garijo, J.M.20
Barniol, R.21
Domínguez, A.22
Rota, R.23
Olcoz, J.L.24
Antón, M.25
Pamplona, X.26
Casanovas, T.27
Jiménez, E.28
Huarte, M.29
Díaz, F.30
Sánchez-Ruano, J.31
Orive, M.32
Muñoz-Sánchez, M.33
Roset, M.34
more..
-
18
-
-
63449113491
-
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study
-
[PMID: 18985810]
-
Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, Fontanges T, Varastet M, Chousterman M, Marcellin P. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008; 14: 6195-6203 [PMID: 18985810]
-
(2008)
World J Gastroenterol
, vol.14
, pp. 6195-6203
-
-
Cacoub, P.1
Ouzan, D.2
Melin, P.3
Lang, J.P.4
Rotily, M.5
Fontanges, T.6
Varastet, M.7
Chousterman, M.8
Marcellin, P.9
-
19
-
-
1842665143
-
Adherence to combination therapy: Influence on sustained virologic response and economic impact
-
[PMID: 15081100 DOI: 10.1016/j.gtc.2003.12.003]
-
Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004; 33: S11-S24 [PMID: 15081100 DOI: 10.1016/j.gtc.2003.12.003]
-
(2004)
Gastroenterol Clin North Am
, vol.33
-
-
Manns, M.P.1
-
20
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
[PMID: 12360468]
-
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069 [PMID: 12360468]
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
Poynard, T.4
Lindsay, K.L.5
Trepo, C.6
Dienstag, J.7
Lee, W.M.8
Mak, C.9
Garaud, J.J.10
Albrecht, J.K.11
-
21
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
[PMID: 19684573 DOI: 10.1038/nature08309]
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
Heinzen, E.L.7
Qiu, P.8
Bertelsen, A.H.9
Muir, A.J.10
Sulkowski, M.11
McHutchison, J.G.12
Goldstein, D.B.13
-
22
-
-
1442308277
-
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well?
-
[PMID: 14996679]
-
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-381 [PMID: 14996679]
-
(2004)
Ann Intern Med
, vol.140
, pp. 370-381
-
-
Zeuzem, S.1
-
23
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
[PMID: 15990196 DOI: 10.1016/j.jhep.2005.04.009]
-
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433 [PMID: 15990196 DOI: 10.1016/j.jhep.2005.04.009]
-
(2005)
J Hepatol
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
Smith, C.I.4
Marinos, G.5
Gonçales, F.L.6
Häussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxì, A.11
Chaneac, M.12
Reddy, K.R.13
-
24
-
-
58149520605
-
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIVcoinfected patients
-
[PMID: 19195330]
-
Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, Salas A, Rey-Joly C, Cirera I, Márquez C, Tor J, Videla S, García-Retortillo M, Clotet B, Solà R. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIVcoinfected patients. Antivir Ther 2008; 13: 1047-1055 [PMID: 19195330]
-
(2008)
Antivir Ther
, vol.13
, pp. 1047-1055
-
-
Tural, C.1
Galeras, J.A.2
Planas, R.3
Coll, S.4
Sirera, G.5
Giménez, D.6
Salas, A.7
Rey-Joly, C.8
Cirera, I.9
Márquez, C.10
Tor, J.11
Videla, S.12
García-Retortillo, M.13
Clotet, B.14
Solà, R.15
-
25
-
-
34548660545
-
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C
-
[PMID: 17875007 DOI: 10.1111/j.1365-2893.2007.00862]
-
Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14: 721-729 [PMID: 17875007 DOI: 10.1111/j.1365-2893.2007.00862]
-
(2007)
J Viral Hepat
, vol.14
, pp. 721-729
-
-
Di Bisceglie, A.M.1
Ghalib, R.H.2
Hamzeh, F.M.3
Rustgi, V.K.4
-
26
-
-
2542590982
-
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
-
[PMID: 15185312 DOI: 10.1002/hep.20212]
-
Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708 [PMID: 15185312 DOI: 10.1002/hep.20212]
-
(2004)
Hepatology
, vol.39
, pp. 1702-1708
-
-
Jeffers, L.J.1
Cassidy, W.2
Howell, C.D.3
Hu, S.4
Reddy, K.R.5
-
27
-
-
17844403232
-
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
-
[PMID: 11481625 DOI: 10.1053/jhep.2001.26371]
-
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403 [PMID: 11481625 DOI: 10.1053/jhep.2001.26371]
-
(2001)
Hepatology
, vol.34
, pp. 395-403
-
-
Lindsay, K.L.1
Trepo, C.2
Heintges, T.3
Shiffman, M.L.4
Gordon, S.C.5
Hoefs, J.C.6
Schiff, E.R.7
Goodman, Z.D.8
Laughlin, M.9
Yao, R.10
Albrecht, J.K.11
-
28
-
-
0032585237
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
-
[PMID: 9807989]
-
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432 [PMID: 9807989]
-
(1998)
Lancet
, vol.352
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
Niederau, C.4
Minuk, G.S.5
Ideo, G.6
Bain, V.7
Heathcote, J.8
Zeuzem, S.9
Trepo, C.10
Albrecht, J.11
-
29
-
-
0034619946
-
Peginterferon alfa-2a in patients with chronic hepatitis C
-
[PMID: 11106715 DOI: 10.1056/NEJM200012073432301]
-
Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672 [PMID: 11106715 DOI: 10.1056/NEJM200012073432301]
-
(2000)
N Engl J Med
, vol.343
, pp. 1666-1672
-
-
Zeuzem, S.1
Feinman, S.V.2
Rasenack, J.3
Heathcote, E.J.4
Lai, M.Y.5
Gane, E.6
O'Grady, J.7
Reichen, J.8
Diago, M.9
Lin, A.10
Hoffman, J.11
Brunda, M.J.12
-
30
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
-
[PMID: 18503773 DOI: 10.1053/j.gastro.2008.04.015]
-
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458 [PMID: 18503773 DOI: 10.1053/j.gastro.2008.04.015]
-
(2008)
Gastroenterology
, vol.135
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Gschwantler, M.4
Maieron, A.5
Brunner, H.6
Stauber, R.7
Bischof, M.8
Bauer, B.9
Datz, C.10
Löschenberger, K.11
Formann, E.12
Staufer, K.13
Steindl-Munda, P.14
-
31
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
[PMID: 16628671 DOI: 10.1002/ hep.21159]
-
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960 [PMID: 16628671 DOI: 10.1002/ hep.21159]
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
Pockros, P.J.4
Reddy, K.R.5
Hadziyannis, S.J.6
Ferenci, P.7
Ackrill, A.M.8
Willems, B.9
-
32
-
-
38649090347
-
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
-
[PMID: 18069698 DOI: 10.1002/hep.22061]
-
Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50 [PMID: 18069698 DOI: 10.1002/hep.22061]
-
(2008)
Hepatology
, vol.47
, pp. 43-50
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
Cozzolongo, R.4
Ricci, G.L.5
Carretta, V.6
Vinelli, F.7
Scotto, G.8
Montalto, G.9
Romano, M.10
Cristofaro, G.11
Mottola, L.12
Spirito, F.13
Andriulli, A.14
-
33
-
-
46249114151
-
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
-
[PMID: 18508296 DOI: 10.1002/hep.22319]
-
Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893 [PMID: 18508296 DOI: 10.1002/hep.22319]
-
(2008)
Hepatology
, vol.47
, pp. 1884-1893
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
Chiu, C.F.4
Yang, Y.H.5
Hou, N.J.6
Lee, L.P.7
Hsieh, M.Y.8
Lin, Z.Y.9
Chen, S.C.10
Hsieh, M.Y.11
Wang, L.Y.12
Chang, W.Y.13
Chuang, W.L.14
-
34
-
-
84655163402
-
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection
-
[PMID: 21912897 DOI: 10.1007/s00535-011-0458-y]
-
Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol 2011; 46: 1427-1436 [PMID: 21912897 DOI: 10.1007/s00535-011-0458-y]
-
(2011)
J Gastroenterol
, vol.46
, pp. 1427-1436
-
-
Weich, V.1
Herrmann, E.2
Chung, T.L.3
Sarrazin, C.4
Hinrichsen, H.5
Buggisch, P.6
Gerlach, T.7
Klinker, H.8
Spengler, U.9
Bergk, A.10
Zeuzem, S.11
Berg, T.12
-
35
-
-
0035098941
-
Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation
-
[PMID: 11207900]
-
Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-195 [PMID: 11207900]
-
(2001)
J Gastroenterol Hepatol
, vol.16
, pp. 190-195
-
-
Hwang, S.J.1
Luo, J.C.2
Chu, C.W.3
Lai, C.R.4
Lu, C.L.5
Tsay, S.H.6
Wu, J.C.7
Chang, F.Y.8
Lee, S.D.9
-
36
-
-
1542616609
-
Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection
-
[PMID: 14748879]
-
Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19: 314-318 [PMID: 14748879]
-
(2004)
J Gastroenterol Hepatol
, vol.19
, pp. 314-318
-
-
Silva, I.S.1
Ferraz, M.L.2
Perez, R.M.3
Lanzoni, V.P.4
Figueiredo, V.M.5
Silva, A.E.6
-
37
-
-
0036882319
-
Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C
-
[PMID: 12498809]
-
Taliani G, Badolato MC, Nigro G, Biasin M, Boddi V, Pasquazzi C, Clerici M. Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C. Clin Immunol 2002; 105: 279-285 [PMID: 12498809]
-
(2002)
Clin Immunol
, vol.105
, pp. 279-285
-
-
Taliani, G.1
Badolato, M.C.2
Nigro, G.3
Biasin, M.4
Boddi, V.5
Pasquazzi, C.6
Clerici, M.7
-
38
-
-
0043037223
-
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
-
[PMID: 12939590 DOI: 10.1053/ jhep.2003.50350]
-
Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/ jhep.2003.50350]
-
(2003)
Hepatology
, vol.38
, pp. 639-644
-
-
Bressler, B.L.1
Guindi, M.2
Tomlinson, G.3
Heathcote, J.4
-
39
-
-
70349290970
-
Genomics: Hepatitis C virus gets personal
-
[PMID: 19759611]
-
Iadonato SP, Katze MG. Genomics: Hepatitis C virus gets personal. Nature 2009; 461: 357-358 [PMID: 19759611]
-
(2009)
Nature
, vol.461
, pp. 357-358
-
-
Iadonato, S.P.1
Katze, M.G.2
-
40
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
[PMID: 19749758 DOI: 10.1038/ng.447]
-
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
Berg, T.4
Weltman, M.5
Abate, M.L.6
Bassendine, M.7
Spengler, U.8
Dore, G.J.9
Powell, E.10
Riordan, S.11
Sheridan, D.12
Smedile, A.13
Fragomeli, V.14
Müller, T.15
Bahlo, M.16
Stewart, G.J.17
Booth, D.R.18
George, J.19
-
41
-
-
36348981708
-
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
-
[PMID: 17894303 DOI: 10.1002/hep.21932]
-
Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-981 [PMID: 17894303 DOI: 10.1002/hep.21932]
-
(2007)
Hepatology
, vol.46
, pp. 971-981
-
-
Jacobson, I.M.1
Brown, R.S.2
Freilich, B.3
Afdhal, N.4
Kwo, P.Y.5
Santoro, J.6
Becker, S.7
Wakil, A.E.8
Pound, D.9
Godofsky, E.10
Strauss, R.11
Bernstein, D.12
Flamm, S.13
Pauly, M.P.14
Mukhopadhyay, P.15
Griffel, L.H.16
Brass, C.A.17
-
42
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
[PMID: 19403903 DOI: 10.1056/NEJMoa0807650]
-
Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650]
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hézode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Bronowicki, J.P.7
Bourlière, M.8
Gharakhanian, S.9
Bengtsson, L.10
McNair, L.11
George, S.12
Kieffer, T.13
Kwong, A.14
Kauffman, R.S.15
Alam, J.16
Pawlotsky, J.M.17
Zeuzem, S.18
-
43
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
[PMID: 19403902 DOI: 10.1056/NEJMoa0806104]
-
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI: 10.1056/NEJMoa0806104]
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
McNair, L.7
Alam, J.8
Muir, A.J.9
|